News Articles for John Van Der Wielen

Orthocell has entered an MOU to secure exclusive distribution rights for Marine Biomedical's innovative bone substitute PearlBone, and lift its stake in the company to 12 per cent.

Murdoch-based Orthocell has announced plans to raise $30 million, as it aims to build further momentum behind its US ambitions.

This week's business appointments include Sue Ellery, John Van Der Wielen, Jeanette Fenske, Neale Fong, and Michael Tamlin.

After a brief hiatus where Rebecca Tomkinson took over, John Van Der Wielen is back in his role as chair of the state government's Future Health Research and Innovation Fund Advisory Council.

WA's medical sector is anxiously awaiting fallout from the US's pharma tariffs, although impending changes could assuage US concerns.

Former deputy prime minister Kim Beazley has stepped down from his role with biotech upshot Orthocell, citing health concerns.

Paul Papalia says he's confident steps taken by Crown Perth to address money laundering concerns have been adequate, and revealed no further penalties would be imposed.

A day after announcing a record quarterly revenue of $2.7 million, Perth medtech Orthocell has appointed a former Pilbara Minerals figure and ex-Olympian to its executive team.

The Perth biotech company has welcomed a US academic for a series of talks at universities across the country.

The two prominent business leaders have different opinions about what should go in the space between the casino and Optus Stadium.

The Crown Perth board has appointed former WA treasurer Ben Wyatt as the incoming chair of the casino, hotel and entertainment business and promoted its financial chief to the top role.

Murdoch-based Orthocell's push to expand the reach of its nerve repair product Remplir has continued, following news it has received regulatory approval in Hong Kong.

Orthocell has posted its fourth consecutive quarter of record revenue, as the regenerative medicine company continues to expand its reach around the globe.

John Van Der Wielen-chaired Orthocell has received another timely boost, as it aims to further a push into Latin America.

Orthocell has received clearance from the US-based Food and Drug Administration to begin selling its nerve repair product Remplir in the country.

Singapore's Health Science Authority has granted regulatory approval for John Van Der Wielen-chaired Orthocell for use of its dental membrane project, Striate+.

Murdoch-based medtech firm Orthocell has continued its expedited expansion push, following news it had lodged an application to sell its nerve repair project Remplir in Canada.

Kim Beazley-backed medtech company Orthocell has flagged an expedited expansion into several jurisdictions after strong early sales of its Remplir nerve repair technology.

Murdoch-based regenerative medicine company Orthocell has posted its third consecutive quarter of record revenue, as it gears up for a final approval from the US FDA for its Remplir nerve product.

Orthocell has submitted its application for US Food and Drug Administration approval for its Remplir nerve regeneration product, marking another moment in a year full of milestones.

Biotech firm Orthocell is a step closer to its nerve repair device Remplir being approved in the US, following the completion of its US regulatory study.

Orthocell has struck a deal with a medical equipment supply firm to distribute its nerve repair device in Singapore, sending the Perth company's shares up 26 per cent.

Perth-based biotechnology firm Orthocell has raised $17 million to take its Remplir nerve regeneration product to the world's biggest healthcare market.

Murdoch-based Orthocell has received regulatory approval to commence sales of Remplir in Singapore, as the listed biotech company posts a second consecutive quarter of record revenue.

Having led multiple corporate transformation projects, John Van Der Wielen shares his thoughts on what works and what doesn't.

Biotechnology company Orthocell will raise $3.5 million, with proceeds put towards its international market expansion strategy.

Mining industry executive Rebecca Tomkinson has taken on a new role as chair of the Future Health Research and Innovation Fund, replacing John Van Der Wielen.

Our weekly appointments wrap includes Di Bain, Rebecca Gravestock, Fiona Notley, Andrew Van Der Merwe, Kim Beazley, Felicity Gooding, Robert Ierace and Simon Theobald.

Former Western Australian governor Kim Beazley has joined the board of Murdoch-based biotechnology company Orthocell, chaired by John Van Der Wielen.

Burns surgeon Fiona Wood has been appointed to the board of John Van Der Wielen-chaired biotechnology company Orthocell as it prepares for international commercialisation.

Crown Perth chair John Van Der Wielen has spoken bluntly about the ‘appalling' failures of the besieged casino, but has avowed the Blackstone-owned organisation can and will be turned around.

Our board moves wrap includes Gregory Bittar, Josh Hunt, Ben Smith, John Van Der Wielen, and Stewart Washer.

John Van Der Wielen will chair Murdoch-based biotechnology company Orthocell as it prepares to scale up manufacturing with a new facility.

Our weekly appointments wrap includes Cassandra Jordan, Malinda Nixon, Chris Eyres, Mark Treasure, John Van Der Wielen, Gavin Tucker, Taylor Conway, Jeremy Hofland, and David Miller.

Not for profits are grappling with remuneration for their directors, with one major group scaling back its payments.

The state government has announced a challenge with a $5 million reward to solve the critical issue of healthcare delivery in the Pilbara.

Crown Resorts boss Steve McCann has stepped down after just over a year in the top job, as John Van Der Wielen is sworn in as casino licensee Burswood Limited's new chair.

Len Buckeridge's eldest son and a former union secretary are the latest additions to the commission that oversees gambling operations in WA.

Blackstone has detailed two development opportunities at Burswood, confirmed John Van Der Wielen as its local chair and conceded governance of its casinos is a work in progress.

The Federal Court has cleared the way for private equity giant Blackstone Group to take over the troubled Crown Resorts business, the last major hurdle for the $8.9 billion acquisition to go ahead.